

Dr. Lindsey Herrel
Urologic Oncologist
2 Podcasts on BackTable
Dr. Lindsey Herrel is a urologic oncologist practicing at the University of Michigan.
Learn from the experiences and expertise of Dr. Lindsey Herrel and other leading voices in your specialty on the BackTable app.

Episode # 245 • 01 Jul 2025
Intravesical Therapies for Intermediate Risk Bladder Cancer
With BCG in short supply and recurrence rates still high, the race is on for better intravesical options. In this episode of BackTable Tumor Board, Dr. Lindsey Herrel, urologic oncologist at the University of Michigan, joins Dr. Ruchika Talwar to explore the evolving landscape of intravesical therapy for intermediate risk bladder cancer.
This podcast is supported by an educational grant from UroGen Pharma. UGN-102 was approved by the FDA on June 12, 2025.
More from Dr. Lindsey Herrel
Loading recent podcasts…
About
Lindsey Herrel MD, MS is a practicing urologic oncologist at the University of Michigan. She is a graduate of the Saint Louis University School of Medicine and completed her residency in urology at Emory University. She received a Master’s of Science in Health and Health Care Research at the University of Michigan where she completed a fellowship in Urologic Oncology and Health Services Research. Her clinical interests focus on the care of patients with urologic malignancies, including cancers of the kidney, testis, prostate, bladder, adrenal gland and penis. Her primary areas of research interest focus in health policy and include understanding the impact of payment reform for safety net hospitals and vulnerable populations.
Visit University of Michigan to learn more about Dr. Lindsey Herrel.
The Materials available on BackTable are provided for informational and educational purposes only and are not a substitute for the independent professional judgment of a qualified healthcare professional in diagnosing or treating patients. Any opinions, statements, or views expressed are those of the individual contributors and do not necessarily reflect those of the publisher, platform, or any affiliated organization.